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A B S T R A C T
Applications of LC-MS/MS for the biochemical diagnosis of catecholamine-producing tumors have fol-
lowed from parallel emergence of this technology with changes in emphasis of biochemical testing, in
particular requirements that testing includemeasurements of plasma or urinary fractionatedmetanephrines.
Since the turn of the century, when LC-MS/MS was ﬁrst introduced into the routine laboratory, there
have been numerous advances in analytical methodology that offer opportunities for breaking away from
out-moded analytical procedures to methods that provide enhanced diagnostic information with dra-
matically improved analytical sensitivity, accuracy and precision as well as rapid sample throughput. LC-
MS/MS also offers high analytical speciﬁcity, but is not infallible. Multiple reaction monitoring does not
always guarantee selectivity and attention to sample puriﬁcation and chromatographic separation remains
important. Although other analytical methods persist, today LC-MS/MS represents the method of choice
for high-throughput, low-cost, precise and accurate measurements of the catecholamine metabolites now
routinely used for diagnosis of catecholamine-producing tumors.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
1.1. Biochemical diagnosis of catecholamine-producing tumors
Catecholamine-producing tumors include pheochromocyto-
mas, paragangliomas and neuroblastomas, all derived from cells of
the neural crest. Pheochromocytomas and paragangliomas (PPGLs)
are tumors of respective adrenal and extra-adrenal chromaﬃn cells
that usually present in adulthood, whereas neuroblastomas are
derived from immature embryonic neuroblast cells that also form
tumors at adrenal and extra-adrenal locations, but present almost
exclusively in childhood.
Both PPGLs and neuroblastomas are characterized by synthesis
and metabolism of catecholamines within tumor cells. Intra-
tumoral metabolism of catecholamines in PPGLs was ﬁrst described
in the 1960s [1]. Nevertheless, because PPGLs are characterized by
hypertension and symptoms of catecholamine excess, those early
ﬁndings were largely ignored and diagnosis continued to focus on
measurements of catecholamines. It was not until the turn of the
century that emphasis started moving from catecholamines to their
O-methylated metabolites, the metanephrines [2].
Shift in emphasis from catecholamines to metanephrines for di-
agnosis of PPGLs followed development of a liquid chromatographic-
electrochemical detection (LC-ECD) method for measuring the
metabolites in plasma [3]. Developed to investigate extra-neuronal
O-methylation pathways of catecholaminemetabolism, that method
established that these pathways were minor routes of metabo-
lism compared to neuronal deamination pathways [4] (Fig. 1). Over
90% of all circulating metanephrine, the metabolite of epineph-
rine, and at least a quarter of all normetanephrine, the metabolite
of norepinephrine, were formedwithin adrenal chromaﬃn cells, not
after release of catecholamines by the sympatho-adrenal system [5].
Tumors derived from chromaﬃn cells were found to produce these
metabolites by the same processes [6]. Since many PPGLs secrete
catecholamines intermittently or in low amounts, the continuous
intra-tumoral metabolism of catecholamines to metanephrines pro-
vides a diagnostic advantage for measurements of the metabolites
over the catecholamines; this is now conﬁrmed by numerous studies
[7]. Consequently, todays recommendations mandate measure-
ments of plasma free or urinary fractionatedmetanephrines as initial
screening tests for PPGLs [7].
Intra-tumoral metabolism of catecholamines is more strongly es-
tablished for neuroblastomas than PPGLs [8]. Neuroblastomas display
a relative lack of catecholamine storage vesicles characteristic of
mature chromaﬃn cells and their PPGL derivatives. Thus, these
tumors usually do not present with hypertension or increased urinary
outputs of catecholamines, so that biochemical diagnosis has always
depended on measurements of catecholamine metabolites.
The two metabolites that have remained the mainstay for di-
agnosis of neuroblastoma are homovanillic acid (HVA) and
vanillylmandelic acid (VMA). HVA represents the end-product of
dopamine metabolism, whereas VMA is the end-product of nor-
epinephrine and epinephrine metabolism [4] (Fig. 1). HVA is
produced by deamination of methoxytyramine, the O-methylated
metabolite, or O-methylation of 3,4-dihydroxyphenylacetic acid, the
deaminated metabolite of dopamine. Both enzymes responsible for
these steps are present in neuroblastoma cells so that HVA can be
directly formed within tumors. In contrast VMA is almost
exclusively formed within the liver by the actions of alcohol dehy-
drogenase on 3-methoxy-4-hydroxyphenylglycol [4]. Thatmetabolite
in turn is formed from deamination of normetanephrine or
O-methylation of 3,4-dihydroxyphenylglycol, the latter largely formed
within sympathetic neurons. Synthesis of norepinephrine re-
quires translocation of dopamine into storage vesicles where the
presence of dopamine-ß-hydroxylase facilitates conversion to nor-
epinephrine. Production of HVA by neuroblastomas thus reﬂects
impaired conversion of dopamine to norepinephrine and the im-
maturity of catecholamine storage and secretory pathways.
Since the HVA and VMA derived from neuroblastomas are diluted
by considerable amounts of the same metabolites produced from
other sources, these metabolites are relatively poor diagnostic
markers for these tumors. In a prospective trial involving 1.5 million
neonates only 73% of all infants detected at follow-up with neuro-
blastoma had elevated urinary excretion of HVA or VMA at screening
[9]. HVA and VMA nevertheless remain the principal catechol-
aminemetabolites used for biochemical diagnosis of neuroblastoma.
The metabolites are excreted in large quantities and are relatively
easy to measure so that in contrast to PPGLs there has been rela-
tively little effort in LC-MS/MS method development directed to
neuroblastoma.
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Fig. 1. Pathways of catecholamine metabolism. *Denotes catecholamine metabo-
lites recommended for routine biochemical diagnosis of pheochromocytomas and
paragrangliomas. †Denotes catecholamine metabolites in routine use for biochem-
ical diagnosis of neuroblastoma. Abbreviations: DA, dopamine; NE, norepinephrine;
EPI, epinephrine; DOPAC, 3,4-dihydroxyphenylacetic acid; MTY, methoxytyramine;
DHPG, 3,4-dihydroxyglycol; NMN, normetanephrine; MN, metanephrine;
HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; MTY-SO4,
methoxytyramine-sulfate; MN-SO4, metanephrine sulfate; NMN-SO4,
normetanephrine sulfate; HVA-SO4, homovanillic acid sulfate; MHPG-SO4, methoxy-
4-hydroxyphenylglycol; MAO, monoamine oxidase; COMT, catechol-O-
methyltransferase; SULT1A3, sulfotransferase type 1A3; ADH, alcohol dehydrogenase;
GI, gastrointestinal.
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1.2. Plasma versus urine measurements
The utility of measurements of metanephrines in plasma instead
of urine for diagnosis of PPGLs was ﬁrst indicated in a series of
studies culminating in a report with cumulative experience in over
800 patients [10]. Although urine fractionated metanephrines pro-
vided the one test for which diagnostic sensitivity approached that
for plasma metanephrines (97% vs 99%), diagnostic speciﬁcity for
measurements in urine was nevertheless lower than for plasma (69%
vs 89%). Higher accuracy of plasma over urinary metanephrines for
diagnosis of PPGLs has been indicated by others [11]. Neverthe-
less, the differences are small and it remains a matter of debate
whether one test is superior to the other. Until resolved, measure-
ments of plasma free and urinary fractionated metanephrines both
remain recommended as initial screening tests for PPGLs [7].
For metanephrines in urine there are other considerations con-
cerning measurements of the free versus deconjugated metabolites,
the latter reﬂecting the sum of free plus conjugatedmetabolites [12].
Metanephrines in urine are usually measured after an acid hydro-
lysis step, in which conjugated metanephines are converted to free
metabolites. The sulfate-conjugates are metabolites produced by a
sulfotransferase enzyme localized mainly to gastro-intestinal tissues
[13] (Fig. 1). Use of an acid-hydrolysis deconjugation step is based
by convention on early methods for which analytical sensitivity was
insuﬃcient for quantiﬁcation of the relatively low concentrations
of free metabolites. With LC-MS/MS, measurements of free
metanephrines are no longer a problem. Although it is not clear
whether urinary free metanephrines offer improved diagnostic per-
formance compared to the deconjugatedmetabolites, there are other
advantages, such as lack of need for acid-hydrolysis deconjugation.
Since eﬃciency of this step depends on pH, temperature and in-
cubation time, variations in these conditions can negatively impact
precision and accuracy of measurements [14].
1.3. Emergence of mass spectrometry
From bioassays, colorimetric and ﬂuorometric methods to
radioenzymatic assays, analytical techniques for diagnosis of
catecholamine-producing tumors have also emerged that employ gas
or liquid chromatography, coupled to electrochemical, ﬂuorometric
or mass spectrometric detection. At the same time there has been
additional emergence of immunoassays for measurements of
metanephrines. Although many early methods for measuring cat-
echolamine metabolites were described that combined gas or liquid
chromatography with a single mass ﬁlter [15–20], these methods in-
volved numerous shortcomings and it was not until emergence of
the triple quadrupole design that mass spectrometry began to take
hold in the routine laboratory environment. As reviewed elsewhere
[21], LC-MS/MS has since risen to the forefront, increasingly taking
center stage as the analytical tool of choice for diagnosis of PPGLs.
Relative freedom from analytical interferences, simpler sample
preparation, as well as high sample throughput, offer signiﬁcant ad-
vantages of LC-MS/MS over other methods (Table 1). Sample
throughput considerations are particularly important for high volume
commercial laboratories where the capital costs of LC-MS/MS in-
strumentation may be easily recouped. For smaller laboratories,
instrument costs, requirements for skilled laboratory personnel and
the need to develop in-house analytics can be a disincentive for LC-
MS/MS, providing advantages for immunoassays supplied as kit
methods. Nevertheless, as outlined in the Endocrine Society
Guidelines on PPGLs, immunoassays are not recommended for mea-
surements of plasma free metanephrines [7]. This is because
immunoassays suffer not only from imprecision, but also from in-
accuracy involving underestimation of plasma concentrations of
metanephrines, a consequence of calibration problems [22].
LC-MS/MS as the analytical technique of choice for laboratory
evaluation of catecholamine-producing tumors has risen to partic-
ular prominence in the United States and Australasia; in the former
economically competitive, high-throughput considerations have been
instrumental to this emergence, whereas in the latter there is value
placed on high level expertise and quality assurance as integral com-
ponents of the chemical pathology profession. Despite the advantages
of LC-MS/MS, over immunoassays, the latter have remained prom-
inent in places where interrelated economic, health insurance and
regulatory issues impede adoption of more advanced laboratory
technologies.
Adoption of technologies requiring advanced expertise can be
particularly diﬃcult in small hospital-based laboratories. Such en-
vironments favor the expense of immunoassay kit methods easily
utilized on available automated immunoassay analyzers. For such
kits and analyzers there areminimal requirements for advanced tech-
nical expertise; there is also no need for a large capital outlay for
instrumentation not easily recouped in a low throughput environ-
ment. For routineuse, kitmethodsmust alsobe certiﬁedby regulatory
agencies and are immediately ready for use, whereas for LC-MS/
MS there can be barriers associated with instrument certiﬁcation
and the need to develop in-housemethods requiring additional time
and expertise for validation to meet regulatory compliance.
Despite the above limitations to emergence of LC-MS/MS, there
remain over-riding advantages that will ensure impact of the tech-
nology even among regions and centers resistant to change (Table 1).
Once expertise is in place and methods are developed, the costs of
consumables are slight compared to kit methods. Modern LC-MS/
MS instruments are also quite robust and ﬂexible allowingmultiple
applications to be run seamlessly on one instrument, therebymini-
mizing problems associated with recouping capital costs of
Table 1
Advantages and disadvantages of LC-MS/MS versus LC-ECD and immunoassays for measurements of catecholamine metabolites
LC-MS/MS LC-ECD Immunoassay
Advantages Advantages Advantages
Minimal consumable costs Minimal consumable costs for in-house methods Minimal expense of instrumentation
High sample throughput Relative simplicity of operation Kit methods simple to set up
Sample preparation relatively simple Some kit methods available, but high consumable costs Minimal operator expertise required
High analytical sensitivity Moderate analytical sensitivity
High analytical speciﬁcity and relative freedom from
interferences
Chromatographic interferences can be identiﬁed
Methoxytyramine can be measured with precision Methoxytyramine measurements possible Disadvantages
High versatility of LC-MS/MS instruments High costs of kit method consumables
Disadvantages Lengthy sample preparation/analysis time
Disadvantages Moderate capital cost of instrumentation Each metabolite must be measured separately
High capital cost of instrumentation Cumbersome sample preparation Diﬃcult to identify presence of interferences
High level of operator expertise required Prone to analytical interferences Poor accuracy – negative bias
Need to develop in-house methods Low sample throughput Poor analytical sensitivity
Not possible to measure methoxytyramine
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instrumentation for low sample throughput laboratories. In-house
methods can also be easily adapted and improved upon,
such as with inclusion of additional analytes to a panel (e.g.,
methoxytyramine). In contrast, for kit methods there is consider-
able expense required by manufacturers in meeting certiﬁcation
standards, so that even if deﬁciencies become recognized theymay
not be acted upon [22]. As covered below there are many continu-
ing advances in LC-MS/MS technology. These developments offer
further opportunities for breaking away from out-moded analyti-
cal procedures to mass spectrometric-based methods that offer
dramatically improved analytical sensitivity, accuracy and preci-
sionwithattendantpotential impact for improvedpatientdiagnostics,
management and care.
2. LC-MS/MS method development
2.1. Analytes and ionization strategies
The analytes used in LC-MS/MS applications directed to diag-
nosis of catecholamine producing tumors include most commonly
normetanephrine, metanephrine and methoxytyramine and less
commonly the parent catecholamines, norepinephrine, epineph-
rine and dopamine measured in plasma or urine (Fig. 2). Urinary
HVA and VMA are also used for diagnosis of neuroblastoma. All are
polar compounds existing as positively (amines) or negatively (acids)
charged ions in solution, favouring electrospray ionization (ESI) as
the method of choice for optimal signal strength. ESI in the posi-
tive mode is standardly used for the amines, whereas negative
electrospray is employed for VMA and HVA.
2.2. Specimen processing
The high analytical speciﬁcity offered by multiple reaction moni-
toring (MRM) in LC-MS/MS applications enables considerably
simpliﬁed sample preparative procedures compared to the labori-
ous procedures demanded by other techniques. Nevertheless, ion
suppression or enhancement associated with matrix impurities still
mandates sample clean up before analysis. For analytes, such as
HVA and VMA, present in urine at high concentrations, this can
simply amount to removal of particulate matter followed by a di-
lution before injection [23]. One method for measurements of urine
deconjugated metanephrines has similarly detailed direct injec-
tion after acid hydrolysis and centrifugation [24]. Usually for such
analytes present in sample matrices at relatively low abundance,
a more involved sample puriﬁcation procedure is necessary;
for plasma free metanephrines, and particularly methoxytyramine,
it can be useful for puriﬁcation to also include analyte
enrichment.
One LC-MS/MS method for plasma metanephrines has been de-
scribed in which puriﬁcation and concentration was achieved by
isopropanol protein precipitation followed by dry down and mobile
phase reconstitution [25]. Virtually all other published methods for
plasma and urinary metanephrines have incorporated a solid phase
extraction (SPE) step [26–39]. Similarly, for the few LC-MS/MS
methods developed for measuring plasma or urine catechol-
amines, either alone [40–42] or in combination with metanephrines
[29,37], all have involved an SPE step.
Sincemetanephrines contain the same functionally chargedamino
group, the most commonly employed SPE process involves cation
exchange [26–30,32,34,36–38]. For catecholamines, methods
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Fig. 2. Chemical structures of catecholamines and O-methylated metabolites (including pathways of metabolism) employed for diagnosis of catecholamine producing tumors
(A) and MRM transitions for normetanephrine employed for mass spectrometric analysis of this metabolite (B). Abbreviations: DBH, dopamine beta hydroxylase; PNMT,
phenylethanolamine-N-methyltransferase; COMT, catechol-O-methyltransferase.
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employing alumina or phenylboronic acid for complexing cat-
echols have been described [41,42], but cation exchange remains
preferable since it also enables combined extraction and measure-
ments of urine free catecholamines andmetanephrines [29,37]. SPE
methods employing weak, strong, or mixed mode reversed phase
strong cation exchange have beendescribed, but in all cases the prin-
cipal is the same, requiring loadingof the sample followedbywashing
and elution steps (Fig. 3). To minimize ion suppression it is impor-
tant that the ﬁnal extract be prepared in a solution identical to or
closely resembling the mobile phase into which the extract is in-
jected, thismost readily achieved by a dry-down and reconstitution
step or elution from SPE cartridges using mobile phase.
SPE sample preparation to date has involved mainly oﬄine ap-
plications [26,27,29,30,32,34,36,37], with online applications
increasingly possible due to advances in robotic instrumentation
[28,38], which in different adaptations is also applicable to oﬄine
applications. Initial SPE procedures employed single unit car-
tridges [26,27,29], which have now been superseded by 96 well SPE
plates [30,32,34,36,37]. Traditionally a vacuum (negative pres-
sure) is applied to SPE columns to draw through the solvents and
sample; however, positive pressure units have been introduced for
the 96 well SPE format that more effectively push rather than pull
the solvents and sample through the SPE material (Fig. 3). The 96
well sample processing format provides substantially increased ef-
ﬁciency, including loading of extracts in 96 well plates directly into
sample and solvent delivery systems. A dry-down andmobile phase
reconstitution step remains possible for measurements in which
sample enrichment can aid analytical sensitivity [36].
Since sample preparation is the main determinant of operator
time and represents a signiﬁcant bottleneck in clinical mass spec-
trometry, automation of the extraction process with coupling to the
chromatographic system provides signiﬁcant gains in eﬃciency and
minimizes sample handling and associated operator errors. Online
SPE also enables increased analytical sensitivity since the sample
can be concentrated before elution, with all of the concentrated
extract injected onto the column. Online SPE systems are de-
signed to automatically process through a series of programmable
functions during which the SPE cartridge is equilibrated, loaded and
washed (Fig. 4).
1. Condition
2. Load
3. Wash
4. Elute
A B
Load onto 
LC-MS/MS
Fig. 3. Experimental set-up for 96-well solid phase extraction using positive pres-
sure (A) and diagrammatic representation of the scheme for cation-exchange SPE
procedures typically used for puriﬁcation of metanephrines prior to loading of 96-
well plates onto the sample manager and solvent delivery system (B). SPE extraction
cartridges are ﬁrst conditioned (1) before samples with internal standards are loaded
(2). There follows a wash step (3) followed by elution of the analytes (4) into 96 well
plates for loading onto the LC-MS/MS.
A B
C D
Fig. 4. Diagrammatic representation of an automated on-line sample puriﬁcation system used for LC-MS/MS measurements of plasma free metanephrines. There are 4 steps
to the process: A equilibration, in which gripper places cartridge in right clamp and high pressure dispenser (HPD) applies conditioning and equilibration solvents to car-
tridge; B sample loading in which the sample manager draws sample during conditioning and equilibration steps, the loop is brought in line with loading solvent from the
HPD and the sample is pushed through the cartridge with the analyte trapped in the cartridge and the stream diverted to waste; C sample washing in which the HPD sup-
plies wash solvents across the cartridge; and D sample elution in which the gripper moves the cartridge to the left clamp for the elution step. The elution time is deﬁned
within the software, providing selectivity of extraction.
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2.3. Liquid chromatography
Initial methods for measurements of plasma free metanephrines
utilised LC-ECD, a labor-intense method that also requires ex-
tended sample run times (up to 40 minutes) for chromatographic
separation of metabolites and interferences [3]. The selectivity offered
by MRM not only enables simpliﬁed sample puriﬁcation, but also
less stringent requirements for chromatographic separation, thereby
reducing sample run times and maximizing sample throughput. In
some applications, there is virtually no chromatographic separa-
tion of metabolites and the purpose of chromatography is to simply
separate polar metabolites from the solvent front and non-polar in-
terferences [28,30,34,38,43]. For these applications, analytical
speciﬁcity depends principally on the selectivity of ion monitoring.
As discussed later and in detail by others [44], over reliance on
the speciﬁcity of the mass spectrometer can be problematic and for
this reason the additional speciﬁcity offered by chromatography
should be balanced against the needs for high sample throughput.
Advances in liquid solvent delivery systems and column technol-
ogy provide opportunities for such optimization. In particular, solvent
delivery systems, such as ultra high performance liquid chroma-
tography (UHPLC) that operate at much higher pressures than
conventional systems enable chromatographers to utilize sub
2-micron particle size columns. The result is increased peak re-
solving power and analytical sensitivity, along with a signiﬁcant
reduction in column re-equilibration time following gradients. The
net gain is faster and superior chromatography facilitated by avail-
ability of a host of analytical columns specially suited for this
purpose.
Analytical columns employing hydrophilic interaction liquid chro-
matography (HILIC) are especially suitable for separation of polar
compounds from matrix interferences and enable enhanced ana-
lytical sensitivity with electro spray ionization. For the desolvation
process, an organic solvent is more eﬃcient and the higher con-
centrations of organic solvent (>80%) used with HILIC provide
superior ionization eﬃciencies than possible with the primarily
aqueous mobile phases required for traditional reverse phase an-
alytical columns. Nevertheless, almost all published applications with
HILIC, although demonstrating rapid chromatography, have dis-
played poor separation of O-methylatedmetabolites [28,30,34,38,43].
Introduction of amide HILIC columns has overcome these issues, al-
lowing separation of O-methylated metabolites while still retaining
the beneﬁts of HILIC (Fig. 5A). Continued use of traditional reverse
phase columns by others reﬂects the more easily attained separa-
tion possible with these columns [24,29,32,35–37], which combined
with UHPLC also enables rapid chromatography at high analytical
sensitivity and speciﬁcity [36,37] (Fig. 5B). Where necessary, im-
provement in separation of amines on reverse phase columns is
possible using ion-pairing reagents [45], but these must be vola-
tile to minimize ion suppression.
2.4. Selectivity, interferences and other analytical issues
Analytical interferences with LC-MS/MS measurements of cat-
echolamines and their metabolites are less troublesome than for
other methods, but as detailed elsewhere [44], may occur in several
different forms: 1. ion suppression or enhancement; 2. ionic cross
talk; 3. in source transformation and; 4 isobaric interferences. Op-
timization of sample puriﬁcation and chromatography as part of
method validation should avoid most problems with ion suppres-
sion. Variable specimenmatrix composition can nevertheless result
in signal loss for isolated samples. For example, as described for HILIC
methods some dugs (e.g., cimetine, ephedrine, labetolol and pseu-
doephedrine) result in ion suppression-associated signal loss, though
with negligible impact on quantiﬁcation [34]. Quantiﬁcation can,
however, be impacted by matrix effects leading to differential ion
suppression and loss of signal for the analyte and its deuterated in-
ternal standard [46].
Ionic cross talk has been described for methods in which
O-methylatedmetabolites are not chromatographically resolved and
where in-source fragmentation can result in formation of ions mim-
icking methoxytyramine, leading to over-estimated concentrations
of this analyte. A larger problem formethoxytyramine has been iden-
tiﬁed to result from co-chromatography of this metabolite with 3-O-
methyldopa, which is present in plasma at concentrations more than
3 orders of magnitude higher than methoxytyramine itself [47]. In
source decarboxylation of 3-O-methyldopa leads to a product ion
identical to that for methoxytyramine (Fig. 6); this results in sub-
stantial overestimation of methoxytyramine, a problem only avoided
by chromatographic separation.
Others have described interferences with measured concen-
trations of normetanephrine by 4-hydroxy-3-methoxyme-
thamphetamine [48], a metabolite of the recreational drug
3,4-methylenedioxymethamphetamine, which also has been re-
ported by others to cause similar interference [34]. The beta-
adrenergic agonists, isoproterenol and isoetharine, are other drugs
reported to interfere respectively with measurements of
normetanephrine and metanephrine [34]. In all above cases the in-
terfering compounds bear structural similarities to measured
O-methylated metabolites and likely interfere by either ionic cross
talk or in source transformation. Isobaric interference can occur
between epinephrine and normetanephrine, which share identi-
cal molecular masses, but is less problematic for catecholamines and
their metabolites than for other analytes (e.g., steroids). In all above
cases interference can be avoided by optimization of chromatography.
Interferences from co-chromatographing substances with MRM
transitions of target analytes can be assessed from ratios of quan-
tiﬁer to qualiﬁer ions. Using these ratios and chromatographic
interferences that precluded baseline resolution, Wright and
B
A
Fig. 5. Ultra-high performace liquid chromatographic separation of normetanephrine
(NMN), metanephrine (MN) andmethoxytyramine (MTY) achieved on an amide HILIC
analytical column (A) compared to a reverse phase analytical column (B).
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colleagues reported interferences with 1% of all patient samples ana-
lyzed by LC-MS/MS for plasma metanephrines [43]. These
investigators further established how these interferences could be
eliminated by MRM with multistage fragmentation, whereby the
conventional product ion produced by collision induced fragmen-
tation of the precursor ion is further fragmented in a linear ion trap
to produce a “second generation product ion”. Although a signiﬁ-
cant advance that takes advantage of hybrid triple quadrupole ion
trap instruments, MRM with multistage fragmentation cannot be
used to resolve interferences resulting from in-source transforma-
tion and in which a product is produced identical to that being
measured. For such interferences chromatographic resolution
remains essential [47].
2.5. Quality assurance
As outlined earlier, one of the disadvantages of LC-MS/MS ap-
plications in the routine clinical chemistry laboratory is the need
for in-house development, which also requires considerable time
for method validation and integration with procedures and pro-
grams to ensure quality assurance (QA). Requirements for method
development and validation have been reviewed elsewhere [49–51].
Reliance on in-house produced calibrators and quality control ma-
terial has been or is being addressed by commercial suppliers. These
efforts are assisting with harmonization of the many varied assay
methods, with this being further facilitated by other practices and
initiatives, in particular those involving inter-laboratory QA pro-
grams [52].
One particularly relevant international QA program for labora-
tory measurements of catecholamines and their metabolites is that
run by the Royal College of Pathologists of Australasia (RCPA). The
RCPA QA program (http://www.rcpaqap.com.au) directed to cat-
echolamines and their metabolites was established by the
Australasian Association of Clinical Biochemists working party on
biogenic amines. The biogenic amines QA program, established in
1988 [53], was extended in 2008 to cover plasma freemetanephrines
[54]. Over the ensuing 7 years there has been a clear shift from
mainly LC-ECD methods to near exclusively LC-MS/MS methods for
measuring plasma metanephrines. Among the 36 laboratories par-
ticipating in the ﬁrst cycle of 2015, 32 (89%) were using LC-MS/
MS, only 1 was using LC-ECD and 3 immunoassays. Apart from
enzyme immunoassays, which continue to show considerable neg-
ative bias and imprecision, there has been a steady improvement
over the 7 years in agreement of results between laboratories.
3. Diagnostics
3.1. Diagnostic performance
As with any laboratory test, accuracy and precision of measure-
ments of catecholamine-related biomarkers are key prerequisites
to ensure best possible diagnostic performance. LC-MS/MS pro-
vides the best currently available analytical tool for such assurance,
but even when performed with high accuracy under the strictest
conditions of quality assurance there can be over-riding more im-
portant factors that impact the performance of any test for diagnosis
of catecholamine-producing tumors [55]. As outlined in the intro-
ductory sections, choice of the best available biomarkers according
to their selectivity for diagnosis is crucial. For biomarkers with poor
diagnostic accuracy, such as urinary HVA and VMA used for detec-
tion of neuroblastoma, evenwhen the analytes aremeasured by state
of the art LC-MS/MS methods, impact of the technology on diag-
nostic performance is unlikely to be signiﬁcant. As discussed below,
high diagnostic performance also remains only possible when testing
for PPGLs is carried out under appropriate preanalytical condi-
tions and with appropriately determined reference intervals.
3.2. Preanalytical considerations
In contrast to analytical interferences, which are less of a problem
with LC-MS/MS than other methods, pharmacophysiological inter-
ferences involving effects on production or clearance of measured
analytes are method-independent and equally important to con-
sider for all methods. Such method-independent interferences can
3-O-Methyldopa
M=211.2
Methoxytyramine
M=167.2
+ESI +ESI
+H+ +H+
+ESI
+H+
Q1 m/z 212.2
[M+H+]
Q1 m/z 151.2
[M-COOH-NH2+H+]
Q1 m/z 151.2
[M-NH3+H+]
Fig. 6. Basis of interference with LC-MS/MS measurements of plasma methoxytyramine due to in-source fragmentation 3-O-methyldopa. Most 3-O-methyldopa remains
insource as the positively charged precursor ion, but a small proportion undergoes insource decarboxylation to a positively-charged ion identical to that produced from
methoxytyramine.
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derive from medications, diet or environmental sources, including
conditions of sampling.
For measurements of normetanephrine, tricyclic and other an-
tidepressants that block neuronal uptake of norepinephrine are one
of the most common causes of false-positive results [56]. There are
numerous other drugs that can either increase norepinephrine
release by sympathetic nerves or impact clearance mechanisms
and thereby cause false positive increases of plasma or urine
metanephrines. As in the case of tricyclics, most such drugs only
increase the likelihood of false positive results so that withdrawal
is only necessary when positive results are encountered.
Monoamine oxidase inhibitors, which block metabolism of
all O-methylated metabolites and cause large increases in
metanephrines, are one exception for which withdrawal is neces-
sary before testing. Although L-dopa used to treat Parkinson’s disease
elevates plasma and urinary outputs methoxytyramine, it has only
minor inﬂuences on normetanephrine and metanephrine mea-
sured by LC-MS/MS [57].
Apart frommedications, dietary inﬂuences can also impact con-
centrations of circulating and urinary catecholamine-related
biomarkers. L-dopa, dopamine and other amines, common to many
foods, are established to increase plasma levels of L-dopa, dopa-
mine and their sulfate-conjugated metabolites [58,59]. Such dietary
compounds can lead to substantial increases of not only urine
outputs of deconjugated normetanephrine and methoxytyramine,
but also plasma free methoxytyramine [60]. Blood samples for mea-
surements of the latter metabolite should therefore be collected after
an overnight fast [61]. For urine, procedures to avoid dietary inﬂu-
ences are problematic and not commonly employed.
For plasma free metanephrines, inappropriate sampling condi-
tions, in particular seated rather than supine blood sampling,
represents the most common and easily correctible cause of false
positive results [55]. Since upright posture is a powerful stimulus
for activating the sympathetic nervous system, sampling in the seated
position results not only in elevated plasma concentrations of nor-
epinephrine, but also its metabolite normetanephrine. False-
positive results may thereby be increased by as much as 7-fold [61].
As indicated by areas under receiver operating characteristic curves,
diagnostic accuracy of plasma free metanephrines measured by LC-
MS/MS for samples taken in seated positions is signiﬁcantly reduced
compared to supine sampling and offers no better if not worse di-
agnostic accuracy compared to urinary fractionated metanephrines.
Thus, when blood cannot be collected in the supine position, any
diagnostic advantage of the plasma over the urine test is negated;
under these circumstances and for ease of measurement the urine
test may be preferable.
3.3. Reference intervals
Because of the potentially deadly consequences of missing the
diagnosis for catecholamine-producing tumors, upper cut-offs of ref-
erence intervals for plasma and urinary metanephrines should
primarily be optimized to ensure high diagnostic sensitivity. Such
optimization provides conﬁdence that patients with the tumors will
not be missed, also meaning that disease can be reliably excluded
by negative results so that no further testing is necessary.
As outlined in published recommendations [7,62], to minimize
false negative results, reference intervals for plasma free
metanephrines must be established for blood sampled in the supine
position. When measurements include plasma methoxytyramine,
reference intervals should also exclude dietary inﬂuences. Dangers
of inappropriately established reference intervals have been high-
lighted by those used in immunoassay kit methods [22]. Upper cut-
offs of reference intervals in package inserts were far too high
resulting in up to a quarter of all patients with PPGLs failing to be
diagnosed. Thus, reference intervals should not be set blindly ac-
cording to kit package inserts or information in textbooks, but should
be validated at every laboratory where the measurements are es-
tablished for routine use (Fig. 7).
Although emphasis of reference intervals used in screening for
PPGLs should primarily be directed to ensuring high diagnostic sen-
sitivity, this does not imply that speciﬁcity should be neglected. For
measurements of plasma normetanephrine, an age-adjustment em-
ploying higher upper cut-offs with advancing age can be particularly
useful for minimizing false-positive results while maintaining high
diagnostic sensitivity [63] (Fig. 7).
For 24 hr urinary measurements, gender can also be important
to consider, with higher upper cut-offs usual in males than females.
Use of age-appropriate reference intervals is also particularly im-
portant for measurements in children [64]. A related consideration
is the use of creatinine for normalizations in spot urines. In con-
trast to 24-hour urinary outputs, urine outputs of normetanephrine
and metanephrine normalized to creatinine show age-associated
decreases, related to increases in total muscle mass and related pro-
duction of creatinine. Similar inﬂuences also impact requirements
for gender-speciﬁc reference intervals for urinary outputs of cat-
echolamine metabolites.
3.4. Methoxytyramine
Methoxytyramine is present in plasma at very low concentra-
tions with upper limits of reference intervals not extending beyond
0.1 nmol/L (Fig. 7). This mandates analytically sensitive detection
methods, currently only possible with any precision using the latest
generation of LC-MS/MS instruments. Although most PPGLs are
readily detected by increases of normetanephrine, either alone or
in combinationwith increases inmetanephrine ormethoxytyramine,
a small percentage aremanifest by solitary increases of metanephrine
and others of methoxytyramine [65]. The latter dopaminergic tumors
display immature phenotypic features often associated with meta-
static disease or with paragangliomas due to mutations of genes
encoding sub-units of succinate dehydrogenase [66,67]. Measure-
ments of methoxytyramine aid detection of these tumors and provide
one of the only currently available circulating biomarkers for
metastatic PPGLs. With technical advances in LC-MS/MS, these mea-
surements should further impact improvements in diagnosis and
management of patients with PPGLs. Extension to neuroblastoma
is another avenue that may offer improvements over current ap-
proaches reliant on urinary HVA and VMA [68].
3.5. Energy pathway metabolites
Apart from applications involving measurements of
catecholamine-related biomarkers, LC-MS/MS-based applications
for aiding diagnosis of patients with PPGLs have also been
directed to measurements of mitochondrial energy pathway me-
tabolites in tumor tissue [69]. This application followed identiﬁcation
of mutations of genes encoding sub-units of succinate dehydroge-
nase as a cause of PPGLs [70,71]. The associated defect in conversion
of succinate to fumarate leads to substantially increased ratios of
the two metabolites in tumor tissue offering a highly sensitive and
speciﬁc method for identifying underlying abnormalities of mito-
chondrial energy metabolism due to genetic defects impacting
associated enzymes [69]. The method is simple, cheap and can be
employed on the same LC-MS/MS instruments used for measure-
ments of catecholamine metabolites, thereby extending associated
diagnostic capabilities.
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